CD4^+CD29^+T细胞含量及其免疫检查点水平与非小细胞肺癌患者的化疗效果及远期存活率的关系  

Study on the relationship between the level of CD4^+CD29^+T cells and the expression of immune checkpoint and the effect of chemotherapy and long-term survival rate in patients with non-small cell lung cancer

作　　者：田文[1] 高敬华[1] 张菁华[1] 李永生[1] TIAN Wen;GAO Jinghua;ZHANG Jinghua;LI Yongsheng(Department of Oncology,Cangzhou Central Hospital,Cangzhou 061000,China)

机构地区：[1]沧州市中心医院肿瘤内科,河北沧州061000

出　　处：《中国肿瘤外科杂志》2020年第1期59-62,共4页Chinese Journal of Surgical Oncology

摘　　要：目的分析CD4^+CD29^+T细胞含量及细胞毒性T淋巴细胞相关抗原4(CTLA-4)、程序坏死因子1(PD-1)及程序坏死因子配体1(PD-L1)免疫检查点表达水平与非小细胞肺癌患者的化疗效果及远期存活率的关系。方法选取2015年1月至2017年1月沧州市中心医院收治的100例非小细胞肺癌患者;采用流式细胞术检测患者血中CD4^+CD29^+T、CTLA-4^+T、PD-1^+T及PD-L1^+T细胞水平;随访2年,记录患者生存情况,分为存活组79例,死亡组21例;依照RECIST Version 1.1标准对患者化疗效果进行评估,并按此分为缓解组54例,进展组46例。比较各组的CD4+CD29+T、CTLA-4^+T、PD-1^+T及PD-L1^+T细胞水平,分析以上各细胞水平与患者疗效及远期存活率之间的相关关系。结果化疗缓解组CD4^+CD29^+T、CTLA-4^+T及PD-1^+T细胞水平均高于进展组[(22.74±1.92)%vs.(18.04±2.15)%、(28.91±1.24)%vs.(20.13±1.77)%、(26.29±1.19)%vs.(18.94±1.64)%],PD-L1+T细胞水平低于进展组[(17.22±1.07)%vs.(22.73±1.25)%],差异均有统计学意义(P<0.05);存活组CD4+CD29+T、CTLA-4+T及PD-1+T细胞水平均高于死亡组[(22.11±1.17)%vs.(14.81±1.64)%、(28.32±1.24)%vs.(11.90±1.93)%、(25.88±2.01)%vs.(11.73±2.06)%],PD-L1+T细胞水平低于死亡组[(16.41±2.72)%vs.(24.81±2.11)%],差异均有统计学意义(P<0.05)。CD4^+CD29^+T、CTLA-4^+T、PD-1^+T细胞水平与患者疗效及远期存活率呈正相关(P<0.05),PD-L1^+T细胞水平与患者疗效及远期存活率呈负相关(P<0.05)。结论非小细胞肺癌患者血中CD4^+CD29^+、CTLA-4^+、PD-1^+T细胞水平与化疗效果及远期生存呈正相关,PD-L1+T细胞水平与其呈负相关关系。Objective To analyze the relationship between the level of CD4^+CD29^+T cells and the expression of CTLA-4,PD-1 and PD-L1 immune checkpoints and the effect of chemotherapy and long-term survival rate in patients with non-small cell lung cancer.Methods One hundred patients with non-small cell lung cancer admitted to our hospital from January 2015 to January 2017 were selected as subjects of study.Fasting venous blood was collected and then the levels of CD4^+CD29^+T cells,CTLA-4^+T cells,PD-1^+T cells and PD-L1^+T cells were detected by flow cytometry.The patients were followed up for two years and treated with chemotherapy according to RECIST Version 1.1 standard.Effectiveness was evaluated,and survival and mortality were recorded.Results The levels of CD4^+CD29^+T cells,CTLA-4^+T cells,PD-1+T cells in blood of remission group and long-term survival group were higher than those of progression group or death group,and the difference was statistically significant(P<0.05).The levels of PD-L1^+T cells were lower than those of progression group or death group,and the difference was statistically significant(P<0.05).The levels of CD4^+CD29^+T cells,CTLA-4^+T cells and PD-1^+T cells were also significantly higher than those of progression group or death group(P<0.05).The levels of CD4^+CD29^+T cells,CTLA There was a significant positive correlation between efficacy and long-term survival,and the difference was statistically significant(P<0.05).The level of PD-L1^+T cells was negatively correlated with the efficacy of chemotherapy and long-term survival,and the difference was statistically significant(P<0.05).Conclusions The levels of CD4+CD29+,CTLA-4^+,PD-1^+T cells were positively correlated with chemotherapy efficacy and long-term survival in patients with non-small cell lung cancer,while PD-L1^+ cells were negatively correlated with them.

关 键 词：癌 非小细胞肺 CD4+CD29+T细胞 免疫检查点 药物疗法 存活率 

分 类 号：R734.2[医药卫生—肿瘤]